COMMUNIQUÉS West-GlobeNewswire

NOTICE OF A GENERAL MEETING OF IBA SA
06/12/2024
NOTICE OF A GENERAL MEETING OF IBA SA 7 January 2025 at 10 a.m. Dear Shareholder, We have the honour of convening you to a General Meeting of IBA (the " GM ") at the Company's [registered office] on 7 January 2025 at 10 [...]
IBA - Information réglementée
06/12/2024
structure actionnariat 20241206.pdf structure actionnariat 20241206.pdf IBA SA – Information réglementée Le 6 décembre 2024,18:00 Publication effectuée en vertu de l’article 15 de la loi du 2 mai 2007 relative à la [...]
IBA - Regulated Information
06/12/2024
IBA SA – Information réglementée Le 6 décembre 2024,18:00 Publication effectuée en vertu de l’article 15 de la loi du 2 mai 2007 relative à la publicité des participations importantes dans des émetteurs dont les actions [...]
The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings
06/12/2024
Bagsværd, Denmark, 6 December 2024 — Today, the European Commission approved Novo Holdings A/S’ acquisition of Catalent, Inc. (Catalent), a global contract development and manufacturing organisation headquartered in New [...]
Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical Seizures
06/12/2024
A 30% reduction in long episodes was shown to be associated with a 50% or greater reduction in clinical seizures in a post-hoc analysis, validating the biomarker for proof-of-concept studies Change in long episode [...]
Neurona Therapeutics Presents Positive Clinical Update: New Data from NRTX-1001 Cell Therapy Trial in Drug-Resistant Epilepsy Announced at 2024 Annual Meeting of the American Epilepsy Society
06/12/2024
– SAFETY : NRTX-1001 has been well-tolerated to date at both high and low doses. No adverse events have been attributed to the cell therapy – LOW DOSE COHORT : 92% median reduction in disabling seizures from baseline, [...]
Spineway provides an update on its activities during a webinar - Arrival of a new CFO
06/12/2024
Press release Ecully, December 6, 2024 – 6 p.m. Spineway provides an update on its activities during a webinar Arrival of a new CFO The Spineway Group, a specialist in innovative implants for the treatment of severe [...]
SPINEWAY fait un point d’activité lors d’un webinaire - Arrivée d’un nouveau directeur financier
06/12/2024
Communiqué de presse Ecully, le 6 décembre 2024 – 18h Spineway fait un point d’activité lors d’un webinaire Arrivée d’un nouveau directeur financier Le groupe Spineway, spécialiste des implants innovants pour le [...]
Virbac : Declaration of the number of shares and voting rights 11/2024
06/12/2024
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]
Virbac : Déclaration d'actions et de droits de vote 11/2024
06/12/2024
DECLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) [...]
CHEO Research Institute and Shriners Hospitals for Children Canada Collaborate to Launch First-of-its-kind Joint Pediatric Metabolic and Genetic Bone Disorders Fellowship
06/12/2024
Note to editors: A media kit , including the press release, biographies, b-roll footage, and still images, will be available upon request. OTTAWA, Ontario, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Shriners Hospitals for [...]
L'Institut de recherche du CHEO et les Hôpitaux Shriners pour enfants Canada collaborent en lançant le premier programme de Monitorat clinique conjoint sur les troubles métaboliques et génétiques de l’os chez l'enfant
06/12/2024
Note pour les rédacteurs : Une trousse pour les médias comprenant le communiqué de presse, les biographies, des séquences vidéo et images fixes sera disponible sur demande. OTTAWA, Ontario, 06 déc. 2024 (GLOBE NEWSWIRE [...]
Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations
06/12/2024
TORONTO, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc (" Psyence Group " or the " Company ") (CSE: PSYG) hereby announces that it has entered into an addendum to the previously announced debt-for-equity swap [...]
AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment
06/12/2024
Segment featuring Dr. Charles Lapp, ME/CFS Key Opinion Leader and founder of the Hunter-Hopkins Center is now available here OCALA, Fla., Dec. 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM [...]
Profound Medical Announces Pricing of US$35 Million Underwritten Public Offering of Common Shares
06/12/2024
BASE SHELF PROSPECTUS IS ACCESSIBLE, AND FINAL PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+ AND ON EDGAR TORONTO, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; [...]
GRI Bio to Participate in the Virtual Investor Closing Bell Series
06/12/2024
Live webcast on Thursday, December 12 th at 4:00 PM ET LA JOLLA, CA, Dec. 06, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline [...]
Kellner Group Urges Stockholders of AIM Immunotech to Vote the Gold Card
06/12/2024
ISS Notes Need for Significant Board Change at AIM Due to Clinical Failure and Lack of Transparency According to ISS – “ There is no question that for shareholders to have any hope of not losing 100 percent of their [...]
Alpha Tau to Participate in Ladenburg’s Oncology Innovators & Investors Symposium
06/12/2024
JERUSALEM, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , today announced [...]
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06/12/2024
DALLAS, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies [...]

Pages